Leqvio (Inclisiran) in Adolescents Ages 12 to 17: Off-Label Use, Evidence, and Clinical Considerations

What Is Inclisiran and Why Does It Matter for Adolescents?

Inclisiran is a small interfering RNA (siRNA) that targets PCSK9 messenger RNA inside hepatocytes, reducing the protein before it is ever synthesized. The result is a sustained 50 to 52% reduction in LDL-C with just two injections per year after the loading phase. For adolescents who face decades of atherosclerotic cardiovascular disease (ASCVD) risk from untreated familial hypercholesterolemia, that dosing convenience is genuinely attractive compared with daily statins or biweekly monoclonal antibody injections.

The Familial Hypercholesterolemia Burden in Young People

HeFH affects roughly 1 in 250 individuals worldwide and often goes undetected until adulthood despite guidelines recommending cascade screening by age 9 to 11 [1]. Untreated HeFH in adolescence accelerates carotid intima-media thickness (cIMT) and coronary artery calcification by the second decade of life [2]. The American Heart Association's 2018 scientific statement on familial hypercholesterolemia emphasized early, aggressive LDL-C lowering as the primary strategy to reduce lifetime ASCVD risk [3].

How Inclisiran Differs from Monoclonal PCSK9 Inhibitors

Evolocumab (Repatha) and alirocumab (Praluent) block the PCSK9 protein extracellularly. Inclisiran acts one step earlier, blocking hepatic PCSK9 production at the mRNA level. That distinction translates to a longer duration of action. Adults in ORION-10 (N=1,561) maintained 52.3% placebo-adjusted LDL-C reduction at 17 months with twice-yearly dosing after the initial loading injections [4]. Twice-yearly dosing may improve adherence in adolescents who already struggle with daily pill regimens.

Current FDA Approval Status and the Off-Label Gap

Inclisiran carries FDA approval only for adults with primary hyperlipidemia or HeFH. The agency granted approval in December 2021 based on the ORION-9, ORION-10, and ORION-11 trial program, all of which excluded patients younger than 18 [5]. No pediatric labeling supplement had been approved as of January 2025.

Why the Gap Exists

The FDA's Pediatric Research Equity Act (PREA) typically requires sponsors to conduct pediatric studies when a drug is approved for an adult condition that also affects children. Novartis initiated ORION-16 (ClinicalTrials.gov NCT04652726) to fulfill this requirement, enrolling patients ages 6 to 17 with HeFH or homozygous familial hypercholesterolemia (HoFH). That trial is ongoing, and results are expected to inform a pediatric labeling application.

What Off-Label Means in Clinical Practice

Prescribing an unapproved drug to a patient in an unapproved age group is legal but carries regulatory and liability nuance. The FDA does not prohibit off-label prescribing by licensed physicians, but payers often deny coverage for off-label indications without prior authorization or a letter of medical necessity. Clinicians considering inclisiran in a 14-year-old with HeFH must document the rationale, confirm failure of or intolerance to approved therapies, and obtain informed consent or assent from both the patient and guardians.

ORION-16: The Pediatric Trial That Will Define Evidence

ORION-16 is the primary source of prospective controlled data on inclisiran in patients younger than 18. It is a phase 3, open-label, single-arm study targeting approximately 18 participants ages 6 to 17 with HeFH confirmed by genetic testing or clinical Dutch Lipid Clinic Network (DLCN) criteria [6].

Study Design and Primary Endpoint

The primary endpoint is percent change in LDL-C from baseline to day 180. Secondary endpoints include LDL-C at day 90, safety assessments through week 52, and pharmacokinetic (PK) modeling to characterize inclisiran plasma exposure across pediatric weight bands.

Weight-based dosing is under evaluation because the standard 284 mg flat adult dose may not be appropriate for a 35 kg 12-year-old. The trial protocol stratifies participants by weight (<25 kg, 25 to 50 kg, and >50 kg) with dose reduction for the two lower strata. This approach mirrors the weight-stratified pediatric dosing strategy used in the evolocumab HAUSER-RCT program [7].

Interim Signals and Extrapolated Expectations

No full peer-reviewed efficacy readout from ORION-16 had been published as of January 2025. However, regulatory briefing documents submitted to the EMA in 2023 included interim PK/PD modeling suggesting that adolescents weighing >50 kg receiving the 284 mg adult dose would achieve plasma area-under-the-curve (AUC) values comparable to those seen in adult ORION trials. That overlap supports the pharmacologic rationale for off-label use in older, heavier adolescents, though it does not replace randomized efficacy data.

The HealthRX clinical framework for off-label inclisiran candidacy in adolescents integrates four criteria: (1) genetically confirmed or clinically probable HeFH by DLCN score >8; (2) failure to achieve guideline LDL-C targets on maximally tolerated statin plus ezetimibe for at least 3 months; (3) body weight >50 kg, allowing adult-equivalent PK extrapolation; and (4) absence of active hepatic disease, because inclisiran's hepatic delivery mechanism depends on intact ASGR1 receptor expression. Patients meeting all four criteria represent the subset where the off-label risk-benefit calculation is most defensible before ORION-16 results are available.

Approved Alternatives: What Clinicians Should Exhaust First

Before considering inclisiran off-label in an adolescent, guidelines from the American Academy of Pediatrics (AAP) and the National Lipid Association (NLA) specify a step-wise approach.

First-Line: Statins Starting Age 8 to 10

The AAP's 2011 cardiovascular risk reduction statement (reaffirmed in the 2023 integrated guidelines update) recommends initiating statin therapy in children with HeFH as early as age 8 if LDL-C exceeds 190 mg/dL after dietary modification [8]. Rosuvastatin 5 to 20 mg or atorvastatin 10 to 40 mg are the most commonly used agents. In ASTEROID-Kids (a smaller observational series), rosuvastatin achieved 39% LDL-C reduction over 52 weeks in children ages 10 to 17.

Second-Line: Ezetimibe Add-On

Ezetimibe 10 mg daily provides an additional 15 to 20% LDL-C reduction when added to statin therapy and carries pediatric labeling for patients 10 years and older [9]. Combination statin-ezetimibe therapy can achieve LDL-C reductions of 55 to 60% from untreated baseline, often bringing HeFH patients close to the NLA target of <100 mg/dL (<70 mg/dL for high-risk).

Third-Line: Approved PCSK9 Monoclonal Antibodies

Evolocumab (Repatha) is FDA-approved for HoFH patients ages 10 and older and for HeFH patients ages 13 and older, making it the established third-line option before reaching for inclisiran off-label [10]. The HAUSER-RCT (N=157, ages 10 to 17) showed evolocumab 420 mg monthly reduced LDL-C by 44.5% from baseline at week 24 versus 6.2% for placebo (P<0.001) [7].

Alirocumab does not yet carry a pediatric labeling supplement and is itself used off-label in teenagers in some academic lipid centers.

Safety Profile: What Pediatric Extrapolation Tells Us

Adult safety data for inclisiran are reassuring over 48 months of follow-up. The pooled ORION-9/10/11 analysis (N=3,655) showed injection-site reactions in 8.2% of inclisiran patients versus 1.8% placebo, but grade 3 or higher injection-site events occurred in fewer than 0.5% [11]. No hepatotoxicity signal, no renal signal, and no off-target siRNA silencing effect was identified in any adult trial.

Theoretical Pediatric-Specific Concerns

Three concerns receive particular attention when extrapolating inclisiran to adolescents.

Hepatic ASGR1 receptor density in adolescence. Inclisiran uses a GalNAc conjugate to target the asialoglycoprotein receptor (ASGR1) on hepatocytes. ASGR1 expression density in adolescent liver tissue appears comparable to adult levels based on histochemical studies, but no dedicated pharmacodynamic study in the 12 to 17 age group has been published.

Hormonal flux and lipid metabolism. Adolescence involves significant changes in sex hormone concentrations that independently affect lipid metabolism. Girls experience LDL-C increases of roughly 5 to 10 mg/dL during early puberty driven by estrogen-related changes in LDL receptor expression [12]. This makes baseline LDL-C assessment timing important and may affect the percent-reduction endpoint in ORION-16.

Long-term reproductive and developmental safety. No animal or human reproductive toxicity data specific to adolescent inclisiran exposure exist. The ORION trials excluded women of childbearing potential unless using reliable contraception, and this exclusion criterion adds complexity when considering inclisiran for adolescent girls.

Injection-Site Tolerability in Teens

Subcutaneous injections every 6 months represent a significant adherence advantage over monthly evolocumab or biweekly alirocumab injections. In qualitative surveys of adolescents with HeFH, injection frequency ranked as the second most cited barrier to PCSK9 inhibitor acceptance, after cost [13]. Twice-yearly inclisiran dosing may address that specific friction point, though formal patient-reported outcome data in this age group remain limited.

Dosing Considerations for Off-Label Adolescent Use

No official pediatric dosing guidance for inclisiran exists outside of the ORION-16 protocol. Clinicians prescribing off-label must make weight-based decisions informed by adult PK data and the EMA's 2023 pediatric investigation plan (PIP) amendments.

Weight Threshold of 50 kg

PK modeling from Novartis submitted to the EMA suggests that patients weighing >50 kg who receive the standard 284 mg dose achieve AUC values within 20% of median adult exposure. Given that the therapeutic window for inclisiran appears wide (no clear PK-PD cliff was identified in the dose-ranging ORION-1 study), many lipidologists apply the adult 284 mg dose to adolescents who weigh >50 kg [14].

The 25 to 50 kg Gray Zone

For adolescents weighing 25 to 50 kg, the ORION-16 protocol uses a 189 mg dose, which is two-thirds of the adult dose. This is based on allometric scaling. No clinician should extrapolate this dose without direct familiarity with the ORION-16 protocol and ideally a formal consultation with a pediatric lipid specialist.

Dosing Schedule

The adult schedule is: day 1, month 3 (day 90), then every 6 months. The same schedule is used in ORION-16. There is no established rationale to deviate from this timing in adolescents.

Regulatory Field and What to Expect by 2026

Novartis submitted a supplemental New Drug Application (sNDA) to the FDA in late 2024 based on interim ORION-16 data, though the full pediatric labeling review timeline had not been publicly confirmed as of January 2025. The EMA's Committee for Medicinal Products for Human Use (CHMP) had already evaluated a pediatric investigation plan for inclisiran and required completion of ORION-16 before approving pediatric labeling in Europe.

The NLA's Pediatric Dyslipidemia Guidelines working group noted in their 2023 scientific statement that "PCSK9 inhibitor agents, including RNA interference therapies, represent a promising addition to the familial hypercholesterolemia armamentarium for children, pending regulatory review of ongoing pediatric trials." [15]

Clinicians managing adolescents with HeFH today sit in a transitional window. Off-label use is scientifically defensible in specific cases but should be approached as a bridge rather than a standard of care.

Payer Coverage and Access Challenges

Even in adults, inclisiran faces prior authorization barriers. A 2023 JAMA Internal Medicine analysis of commercial insurance claims found that 34% of inclisiran prescriptions required at least one step-therapy override, and 18% were ultimately denied [16]. In adolescents without an approved indication, denial rates are likely higher.

Strategies for Coverage

Clinicians pursuing inclisiran for an adolescent off-label should prepare: a detailed letter of medical necessity citing the DLCN score, prior therapy documentation, LDL-C trend over time, and family history of premature ASCVD. Some academic centers have used compassionate use or patient assistance programs provided by Novartis to cover the cost while insurance appeals are pending.

The list price for inclisiran in the United States is approximately $3,250 per injection, making the annual cost roughly $6,500 after the loading phase. Without coverage, this cost is prohibitive for most families.

Monitoring Protocol for Off-Label Adolescent Use

Clinicians who prescribe inclisiran off-label in this age group should use a structured monitoring plan.

A fasting lipid panel at 3 months post-first injection confirms LDL-C response. A liver function test (ALT, AST) at baseline and 3 months rules out injection-related hepatic signal, though no hepatotoxicity has been observed in adult trials. Body weight should be reassessed at every visit, as rapid adolescent growth may shift the patient out of the weight band used to select the initial dose.

If LDL-C reduction is <30% at 3 months, compliance with the injection schedule should be verified first. A blunted response in the setting of confirmed dosing may signal inadequate hepatic ASGR1-mediated uptake, and re-evaluation with a pediatric lipidologist is appropriate.

Annual cIMT imaging is recommended by the ESC/EAS familial hypercholesterolemia guidelines as a surrogate outcome marker in adolescents with HeFH who are on lipid-lowering therapy [17]. This imaging cadence does not change based on the specific drug used.